| Q49797952 | 18F-AlF Labeled Peptide and Protein Conjugates as Positron Emission Tomography (PET) Imaging Pharmaceuticals. |
| Q52654885 | 18F-PSMA-1007 PET/CT at 60 and 120 minutes in patients with prostate cancer: biodistribution, tumour detection and activity kinetics. |
| Q47963642 | A PSMA Ligand Labeled with Cobalt-55 for PET Imaging of Prostate Cancer. |
| Q92190795 | Biodistribution and radiation dosimetry of [18F]-JK-PSMA-7 as a novel prostate-specific membrane antigen-specific ligand for PET/CT imaging of prostate cancer |
| Q92662612 | Current Status of PSMA-Radiotracers for Prostate Cancer: Data Analysis of Prospective Trials Listed on ClinicalTrials.gov |
| Q47241139 | Current status of theranostics in prostate cancer. |
| Q90356310 | Diagnostic performance of 18F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer |
| Q100395448 | Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology |
| Q37662669 | F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients |
| Q104064616 | Intra-individual dynamic comparison of 18F-PSMA-11 and 68Ga-PSMA-11 in LNCaP xenograft bearing mice |
| Q55023828 | PSMA Theranostics: Current Status and Future Directions. |
| Q38647632 | Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging |
| Q47156816 | Procedures for the GMP-Compliant Production and Quality Control of [18F]PSMA-1007: A Next Generation Radiofluorinated Tracer for the Detection of Prostate Cancer. |
| Q92410918 | Prostate Cancer Energetics and Biosynthesis |
| Q45753373 | Radiochemistry and Preclinical PET Imaging of 68Ga-Desferrioxamine Radiotracers Targeting Prostate-Specific Membrane Antigen |
| Q89529826 | Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology |
| Q47779789 | Simultaneous whole-body 18F-PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: a pilot study |
| Q89710944 | Synthesis, Labeling and Preclinical Evaluation of a Squaric Acid Containing PSMA Inhibitor Labeled with 68 Ga: A Comparison with PSMA-11 and PSMA-617 |
| Q90075017 | [68Ga]Ga-DOTA-TOC: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging |
| Q52937814 | [Significance of PSMA imaging in prostate cancer]. |